Oriola-KD and MSD renew their long-term cooperation agreement in Finland

Oriola-KD Corporation Stock Exchange Release 17 September 2015 at 10 a.m.

Oriola-KD and MSD renew their long-term cooperation agreement in Finland

Oriola-KD and MSD BV, MSD's Dutch subsidiary and primary supplier for the Nordic region, have signed a new long-term cooperation agreement on 17 September 2015. According to the cooperation agreement, Oriola-KD offers MSD pharmaceutical storage and distribution services and a broad range of tailored services in Finland.

MSD develops new and innovative pharmaceuticals. In Finland, it focuses on diabetes, immunology, oncology, infectious diseases, cardiovascular diseases and central nervous system disorders. MSD invests heavily in pharmaceutical research. In 2006-2014 MSD's investments in pharmaceutical research in Finland were approximately EUR 10 million annually and included more than 17,000 patients. The sales of MSD's pharmaceuticals at wholesale prices was EUR 136 million in Finland in 2014 (source: IMS Health).

Oriola-KD Corporation

Eero Hautaniemi
President and CEO

For further information, please contact:

Eero Hautaniemi
President and CEO
tel. +358 10 429 2109
eero.hautaniemi@oriola-kd.com

Distribution:
NASDAQ OMX Helsinki Ltd.
Key media

Released by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo
www.oriola-kd.com

HUG#1952636